EP4719386A2 - Hétérocycles bicycliques saturés 5,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3 - Google Patents

Hétérocycles bicycliques saturés 5,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3

Info

Publication number
EP4719386A2
EP4719386A2 EP24816266.1A EP24816266A EP4719386A2 EP 4719386 A2 EP4719386 A2 EP 4719386A2 EP 24816266 A EP24816266 A EP 24816266A EP 4719386 A2 EP4719386 A2 EP 4719386A2
Authority
EP
European Patent Office
Prior art keywords
methyl
trifluoromethyl
pyridazin
phenol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24816266.1A
Other languages
German (de)
English (en)
Inventor
Zachary G. BRILL
Chen CHENG
Donna A. A. W. HAYES
Kyle S. MCCLYMONT
Rohan Rajiv Merchant
Essam Metwally
Anilkumar G. Nair
Ning Qi
Brandon M. Taoka
Maoqun TIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of EP4719386A2 publication Critical patent/EP4719386A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés de formule structurale (I), et leurs sels pharmaceutiquement acceptables, qui sont des inhibiteurs de NLRP3 et peuvent être utiles dans le traitement, la prévention, la gestion, l'amélioration, le contrôle et la suppression de maladies médiées par NLPR3. Les composés de la formule développée (I) peuvent être utiles dans le traitement, la prévention ou la gestion de maladies, de troubles et d'états médiés par NLRP3 tels que, mais sans s'y limiter, la goutte, la pseudo-goutte, le CAPS, la fibrose NASH, l'insuffisance cardiaque, la péricardite idiopathique, la dermatite atopique, la maladie intestinale inflammatoire, la maladie d'Alzheimer, la maladie de Parkinson et le traumatisme crânio-cérébral.
EP24816266.1A 2023-06-02 2024-05-28 Hétérocycles bicycliques saturés 5,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3 Pending EP4719386A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363505794P 2023-06-02 2023-06-02
PCT/US2024/031214 WO2024249389A2 (fr) 2023-06-02 2024-05-28 Hétérocycles bicycliques saturés 5,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3

Publications (1)

Publication Number Publication Date
EP4719386A2 true EP4719386A2 (fr) 2026-04-08

Family

ID=93658845

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24816266.1A Pending EP4719386A2 (fr) 2023-06-02 2024-05-28 Hétérocycles bicycliques saturés 5,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3

Country Status (2)

Country Link
EP (1) EP4719386A2 (fr)
WO (1) WO2024249389A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025153532A1 (fr) 2024-01-16 2025-07-24 NodThera Limited Polythérapies faisant intervenir des inhibiteurs de nlrp3 et des agonistes de glp-1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
JP6487921B2 (ja) * 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
HRP20240935T1 (hr) * 2018-06-27 2024-11-22 Ptc Therapeutics, Inc. Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
CA3199652A1 (fr) * 2020-11-20 2022-05-27 Matthew Netherton Composes et utilisations associees
WO2024094150A1 (fr) * 2022-11-04 2024-05-10 Insilico Medicine Ip Limited Inhibiteurs de l'inflammasome nlrp3 et leurs utilisations

Also Published As

Publication number Publication date
WO2024249389A2 (fr) 2024-12-05
WO2024249389A3 (fr) 2025-04-17

Similar Documents

Publication Publication Date Title
JP7707451B2 (ja) Ｎｏｄ様受容体タンパク質３の阻害剤として有用なフタラジン誘導体
US12516046B2 (en) 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors
WO2024137319A1 (fr) Hétérocyles bicycliques 6,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3
WO2021257420A1 (fr) 2-oxoimidazolidine-3-carboxamides utiles en tant qu'inhibiteurs de nav1.8
WO2022235859A1 (fr) Cycloalkyl 3-oxopipérazine carboxamides et cyclohétéroalkyle 3-oxopipérazine carboxamides en tant qu'inhibiteurs de nav1.8
CA2954091C (fr) Composes 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one et leur utilisation comme modulateurs allosteriques negatifs des recepteurs mglur2
WO2024097598A1 (fr) Triazines utiles comme inhibiteurs de la protéine réceptrice de type nod 3
WO2022166741A1 (fr) Composé macrocyclique contenant un benzohétérocycle et agissant en tant qu'inhibiteur de la kinase egfr et composition pharmaceutique et utilisation de celui-ci
TW202413371A (zh) 作為pde4b抑制劑的含氮雜環類化合物
TWI879050B (zh) 一系列含氮橋雜環化合物及其製備方法
WO2024249389A2 (fr) Hétérocycles bicycliques saturés 5,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3
JP7815552B1 (ja) Ｎｏｄ様受容体タンパク質３の阻害薬として有用な５，６－不飽和二環式ヘテロ環
JP2025023868A (ja) Ｎｏｄ様受容体タンパク質３の阻害剤として有用なフタラジン誘導体
JP2026009108A (ja) Ｎｏｄ様受容体タンパク質３の阻害薬として有用な５，６－不飽和二環式ヘテロ環
US20250195511A1 (en) Indazole derivatives useful as inhibitors of nod-like receptor protein 3
WO2025128781A1 (fr) Dérivés d'azaindazole utiles en tant qu'inhibiteurs de la protéine réceptrice de type nod 3
EA052925B1 (ru) Производные фталазина, пригодные в качестве ингибиторов белка 3 nod-подобного рецептора
WO2026047577A1 (fr) Dérivés d'hydroquinazoline et traitement d'une maladie ou d'un trouble à l'aide de ceux-ci
JP2025517615A (ja) ニコチンアセチルコリン受容体リガンド

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260102

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR